| sorafenib / Generic mfg. |
NCT00493636: 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy |
|
|
| Completed | 2b | 160 | US | Gemcitabine, Gemzar, Sorafenib, Nexavar, Placebo, Sugar pill, Capecitabine, Xeloda | Accelerated Community Oncology Research Network, Amgen | Breast Cancer | 09/10 | 11/12 | | |
|
|
|
NCT00101400: BAY43-9006 - Phase II in Advanced Breast Cancer |
|
|
| Completed | 2 | 54 | Europe | Sorafenib (Nexavar, BAY43-9006) | Bayer | Breast Neoplasms, Breast Cancer | 01/06 | 01/08 | | |
NCT00096434: Sorafenib in Treating Patients With Metastatic Breast Cancer |
|
|
| Completed | 2 | 23 | US | sorafenib tosylate, laboratory biomarker analysis | National Cancer Institute (NCI) | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | 06/06 | | | |
NCT00632541: A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer |
|
|
| Terminated | 2 | 18 | US | Sorafenib, Bevacizumab, Imaging | Hoosier Cancer Research Network, Genentech, Inc., Bayer, Amgen | Metastatic Breast Cancer | 03/09 | 03/09 | | |
|
NCT00607438: A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Terminated | 2 | 16 | US | Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane), Abraxane, Sorafenib (Nexavar), Nexavar | Veeda Oncology, Bayer, Celgene Corporation | Breast Cancer | 05/09 | 05/09 | | |
NCT00722072: Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy |
|
|
| Terminated | 2 | 12 | US | fulvestrant, sorafenib tosylate | OHSU Knight Cancer Institute, National Cancer Institute (NCI) | Breast Cancer | 07/10 | 07/12 | | |
| Completed | 2 | 36 | Europe | Nexavar (Sorafenib) | German Breast Group, Bayer | Breast Cancer | 09/11 | 12/11 | | |
NCT00525161: Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer |
|
|
| Terminated | 2 | 11 | US | sorafenib, Nexavar | Suleiman Massarweh, Bayer | Breast Cancer | 01/13 | 01/15 | | |
NCT00573755: Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer |
|
|
| Terminated | 2 | 4 | US | anastrozole, exemestane, letrozole, sorafenib tosylate, placebo | Mayo Clinic, National Cancer Institute (NCI) | Breast Cancer | 04/13 | 04/13 | | |
|
| Completed | 2 | 59 | Europe | Paclitaxel and Sorafenib, sorafenib = nexavar, Paclitaxel | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH, iOMEDICO AG | Metastatic Breast Cancer | 08/14 | 08/14 | | |
NCT01194869: Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer |
|
|
| Terminated | 2 | 25 | US | Sorafenib, Nexavar, Cisplatin, Platinol, CDDP, Cis-diamminedichloroplatinum(II), Paclitaxel, Taxol | Emory University, Amgen, Bayer | Breast Cancer | 06/15 | 06/15 | | |
NCT01762150: Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma |
|
|
| Completed | 2 | 26 | RoW | Sorafenib, Nexavar, Gemcitabine, Gemzar, Cisplatin, Cis-Dichlorodiamineplatinum | Peking University Cancer Hospital & Institute, Bayer | Renal Cell Carcinoma | 12/16 | 06/18 | | |
|
NCT00217399: Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 35 | US | sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, anastrozole, ANAS, Arimidex, ICI-D1033 | National Cancer Institute (NCI) | Recurrent Breast Cancer, Stage IV Breast Cancer | 07/09 | 01/13 | | |
NCT00825734: Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 83 | US | Sorafenib, Nexavar (Sorafenib), Ixabepilone, Ixempra (Ixabepilone) | SCRI Development Innovations, LLC, Bayer, Bristol-Myers Squibb | Metastatic Breast Cancer | 06/13 | 08/14 | | |
|
NCT00828074: Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer |
|
|
| Completed | 1/2 | 46 | US | sorafenib tosylate, vinorelbine ditartrate | City of Hope Medical Center, National Cancer Institute (NCI) | Breast Cancer | 04/14 | 04/14 | | |
|
